Cinnarizine is an antihistamine and calcium channel blocker of the diphenylmethylpiperazine group. It is also known to promote cerebral blood flow, and so is used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis. However, it is more commonly prescribed for nausea and vomiting due to motion sickness or other sources such as chemotherapy, vertigo, or Ménière's disease.
Market Analysis and Insights: Global Cinnarizine Market
Due to the COVID-19 pandemic, the global Cinnarizine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Hospital accounting for % of the Cinnarizine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Antiemetic Agent segment is altered to an % CAGR throughout this forecast period.
China Cinnarizine market size is valued at US$ million in 2021, while the US and Europe Cinnarizine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Cinnarizine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Cinnarizine include Goodwill Pharma, Zambon, Gedeon Richter, Johnson and Johnson, Hasco-Lek, Teva, Sopharma, Aurobindo Pharma and Novartis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Cinnarizine Scope and Segment
Cinnarizine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Cinnarizine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Hospital
Drug Store
On-line
Segment by Application
Antiemetic Agent
Histamine H₁-Receptor Antagonist
Antivertigo Agent
By Company
Goodwill Pharma
Zambon
Gedeon Richter
Johnson and Johnson
Hasco-Lek
Teva
Sopharma
Aurobindo Pharma
Novartis
Mylan
Eurogenerics
Nidda Healthcare
Apotex
Leti Pharma
Allena Pharmaceuticals
Inga Laboratories
March Pharma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE